Pacira BioSciences, Inc. (PCRX) Stock Price & Analysis

Pacira BioSciences, Inc. (PCRX) closed at USD 36.39 on Thursday, October 29, 2026, up 0.00% on the day. The US market is currently closed (after-hours); this is not a live price.

The prior close was USD 36.39; the Oct 29, 2026 session ranged USD 36.37–36.4 on volume of 618,925 shares. Market capitalization is $1.45B, with a 52-week range of USD 18.8–36.67 (NMS). Source: Nexqual, retrieved October 29, 2026 at 23:43 UTC.

Also available as compact Markdown for AI agents: nexqual.com/PCRX.md

Key facts (PCRX)

• Last four reported quarters (through Jun 30, 2026): revenue $746M, net income $14.6M (2.0% margin), free cash flow $180M (SEC filings).
• Valuation: P/E 99.2x (avg 103.8x at the last 2 fiscal year-ends), EV/EBITDA 20.5x, net debt $112M.
• Insider open-market sales, last ~7 months: 6 Form 4 filings, $1.3M; 0 not under a Rule 10b5-1 plan ($0K); 1 by opportunistic insiders (0 outside 10b5-1 plans), 3 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Hold (mean 3.00 on a 1–5 scale) (9 analysts), mean target USD 33.57 (range 25–36.5).
• Total return with dividends: 1Y +71.1% vs S&P 500 +14.4%; 5Y -30.4% vs S&P 500 +79.1%.
• Next earnings: 2026-11-05 (date not yet confirmed by the company), EPS estimate USD 0.73, revenue estimate $183M. All companies reporting that day: https://nexqual.com/earnings/2026-11-05
• Dividend: PCRX paid no cash dividend in the last five years.
• Short interest: 15.33% of float (as of 2026-10-15), 1.9 days to cover.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (PCRX)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (PCRX)

P/E 99.2x · P/S 1.9x · EV/EBITDA 20.5x · EV/Sales 2.1x · P/FCF 8.1x · P/B 2.2x · FCF yield 12.36% · Earnings yield 1.01% · Buyback yield (TTM) 10.21% · Net debt $112M · EV $1.56B

P/E at fiscal year-ends: Dec 2025 165.7x, Dec 2023 41.8x.

Insider sales (SEC Form 4, open-market, last ~7 months) (PCRX)

6 of 6 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (PCRX)

Consensus Hold (mean 3.00 on a 1–5 scale), 9 analysts; mean target USD 33.57 (low 25, high 36.5).

Rating changes, last 120 days:

Total return (dividends reinvested) (PCRX)

Dividends (PCRX)

PCRX paid no cash dividend in the last five years.

Short interest (PCRX)

4,260,076 shares sold short, 15.33% of the float, as of Oct 15, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 15, 2026): 7,561,153 shares (-43.7%). Days to cover: 1.9 (short shares ÷ average daily volume).

PCRX earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

PCRX recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

PCRX suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Feb 26, 2026.

PCRX company outlook (results filed Aug 4, 2026)

• “The company is reiterating its remaining full-year 2026 guidance as follows: • EXPAREL net product sales of $600 million to $620 million; • Non-GAAP gross margin of 77 percent to 79 percent; and • Non-GAAP R&D expense of $105 million to $115 million.”

Quoted word-for-word from the SEC 8-K results press release.

PCRX analyst estimates and revisions

Key Statistics (as of October 29, 2026 at 23:43 UTC)

Technical Analysis (PCRX)

Nexqual's technical model rates PCRX "BUY" based on 5 bullish and 1 bearish signals across 127 daily candles, as of October 29, 2026 at 23:43 UTC.

Analyst Ratings (PCRX)

Wall Street analysts rate PCRX "Hold" based on 9 analysts, with a mean price target of USD 33.57 (range USD 25–36.5), per Nexqual as of October 29, 2026 at 23:43 UTC.

Earnings (PCRX)

Recent Earnings History

Source: Nexqual, October 29, 2026 at 23:43 UTC.

Financials & Fundamentals (PCRX)

Source: Nexqual, October 29, 2026 at 23:43 UTC.

Financial Health Score (PCRX)

Nexqual rates Pacira BioSciences, Inc.'s overall financial health "Solid" across five dimensions, as of October 29, 2026 at 23:43 UTC.

Ownership (PCRX)

Source: Nexqual, October 29, 2026 at 23:43 UTC.

Leadership (PCRX)

Pacira BioSciences, Inc. is led by Frank D. Lee, CEO & Director, per Nexqual as of October 29, 2026 at 23:43 UTC.

Major Backers & Investors (PCRX)

Notable institutional backers of Pacira BioSciences, Inc. include Doma Perpetual Capital Management LLC, Shaw D.E. & Co., Inc., Renaissance Technologies, according to Nexqual as of October 29, 2026 at 23:43 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 29, 2026 at 23:43 UTC.

From Pacira BioSciences, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)

Key Strengths & Strategy (as disclosed to the SEC)

• In November 2023, the FDA approved our supplementary New Drug Application, or sNDA, to expand the EXPAREL label to include administration in adults as an adductor canal block and a sciatic nerve block in the popliteal fossa.
• PCRX-201 is the lead program from our proprietary high-capacity adenovirus, or HCAd, vector platform, which enables local administration of genetic medicines and has the potential to unlock gene therapy for large prevalent diseases affecting millions of people.
• Our proprietary HCAd vector platform solves many of the challenges in the field of genetic medicine that have prevented its utilization in treating common diseases like OA.
• We have built our sales and marketing organization to commercialize our products.

Partnerships

• We are currently sponsoring a prospective, real-world registry called the Innovations in Genicular Outcomes Registry, or IGOR, which is a patient-focused registry governed in collaboration with a steering committee of scientific experts that evaluates clinical, economic- and health-related patient-reported outcomes in patients who have received any treatment for knee OA pain, including TKA.
• Designed in collaboration with specialists in orthopedic surgery, sports medicine, physiatry rheumatology, and family medicine, the registry follows patients for multiple years, but at least a minimum of 18 months.

Legal & Regulatory Risks (Item 1A, quoted)

• Our business could be materially adversely affected if a regulatory or enforcement agency determines that we are promoting or have in the past promoted the "off-label" use of our products.
• Pacira BioSciences, Inc. | 2025 Annual Report on Form 10-K | 49
• We are unable to predict whether any future regulatory actions will have an effect on our product sales, and even if such actions are ultimately resolved favorably, our sales may suffer due to reputational or other concerns.
• We may not receive regulatory approval for any of our product candidates, or the approval may be delayed for various reasons, including successful challenges to the FDA's interpretation of Section 505(b)(2), which would have a material adverse effect on our business and financial condition.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 23:43 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt